Literature DB >> 32473602

Concomitant lansoprazole ameliorates cisplatin-induced nephrotoxicity by inhibiting renal organic cation transporter 2 in rats.

Shun-Ichi Hiramatsu1, Kenji Ikemura2, Yutaka Fujisawa3, Takuya Iwamoto4, Masahiro Okuda2.   

Abstract

Cisplatin is used widely for the treatment of multiple solid tumors. Cisplatin-induced nephrotoxicity is caused by renal accumulation of cisplatin via human organic cation transporter 2 (hOCT2). As lansoprazole, a proton pump inhibitor, is known to inhibit hOCT2 activity, lansoprazole might ameliorate cisplatin-induced nephrotoxicity. A previous study showed that concomitant lansoprazole administration ameliorated nephrotoxicity in patients receiving cisplatin. However, the detailed mechanism remains to be clarified. In the present study, the drug-drug interaction between lansoprazole and cisplatin was examined using hOCT2-expressing cultured cells and rat renal slices. Moreover, the effect of lansoprazole on cisplatin-induced nephrotoxicity and the pharmacokinetics of cisplatin in rats was investigated. In the uptake study, lansoprazole potently inhibited the uptake of cisplatin in hOCT2-expressing cultured cells and rat renal slices. The in vivo rat study showed that concomitant lansoprazole significantly ameliorated cisplatin-induced nephrotoxicity and reduced the renal accumulation of platinum up to approximately 60% of cisplatin alone at 72 h after cisplatin intraperitoneal administration. Furthermore, the renal uptake of platinum at 3 min after intravenous cisplatin administration in rats with cisplatin and lansoprazole decreased to 78% of rats with cisplatin alone. In addition, there was no significant difference in the plasma platinum concentration between rats treated with and without lansoprazole at 3 min after cisplatin intravenous administration. These findings suggested that concomitant lansoprazole ameliorated cisplatin-induced nephrotoxicity by inhibiting rOCT2-mediated cisplatin uptake in rats, thus decreasing cisplatin accumulation in the kidney. The present findings provided important information for the establishment of novel protective approaches to minimize cisplatin-induced nephrotoxicity.
© 2020 John Wiley & Sons, Ltd.

Entities:  

Keywords:  cisplatin; lansoprazole; nephrotoxicity; organic cation transporter 2

Mesh:

Substances:

Year:  2020        PMID: 32473602     DOI: 10.1002/bdd.2242

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  4 in total

1.  Analysis of Risk Factors for High-dose Cisplatin-induced Renal Impairment in Head and Neck Cancer Patients.

Authors:  Hiroyoshi Koide; Satoshi Noda; Yumi Okunuki; Shigehiro Owaki; Takeshi Shimizu; Tomohiro Terada; Shin-Ya Morita
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

2.  An Integrated In Silico and In Vivo Approach to Identify Protective Effects of Palonosetron in Cisplatin-Induced Nephrotoxicity.

Authors:  Eri Wakai; Yuya Suzumura; Kenji Ikemura; Toshiro Mizuno; Masatoshi Watanabe; Kazuhiko Takeuchi; Yuhei Nishimura
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-20

3.  Repositioning of Lansoprazole as a Protective Agent Against Cisplatin-Induced Ototoxicity.

Authors:  Eri Wakai; Kenji Ikemura; Toshiro Mizuno; Kazuhiko Takeuchi; Satoshi Tamaru; Masahiro Okuda; Yuhei Nishimura
Journal:  Front Pharmacol       Date:  2022-07-15       Impact factor: 5.988

4.  Omeprazole Prevents Colistin-Induced Nephrotoxicity in Rats: Emphasis on Oxidative Stress, Inflammation, Apoptosis and Colistin Accumulation in Kidneys.

Authors:  Mohammed Z Nasrullah; Khalid Eljaaly; Thikryat Neamatallah; Usama A Fahmy; Abdulmohsin J Alamoudi; Hussain T Bakhsh; Ashraf B Abdel-Naim
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.